Merck & Co. is dropping just over $1 billion to acquire Peloton Therapeutics, a privately-held biotech working on small molecule medicines that target a protein which, when mutated, can foster tumor development.
Peloton's most advanced drug is under investigation as a treatment for kidney cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,